CD55 / DAF Antibody ( FITC )

CD55 / DAF Antibody Datasheet

CD55 / DAF Antibody Product Information

• Immunogen: Recombinant Human CD55 protein (Catalog#10101-H08H)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 8A8C10G5
• Ig Type: Mouse IgG1
• Concentration: 5 μl/Test, 0.2 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD55 / DAF (rh CD55 / DAF; Catalog#10101-H08H; NP_000565.1; Met 1-Ser 353) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

CD55 / DAF Antibody Usage Guide

• Specificity: Human CD55 / DAF
• Flow Cytometry:
  

  Profile of anti-CD55 reactivity on K562 cells analyzed by flow cytometry.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

CD55 / DAF Antibody Background

CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. This 70-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It interferes with the functions of C3 and C5 convertases in both the classical and alternative pathways by preventing the assembly of the C3bBb complex or accelerating the disassembly of preformed convertase, and thus disrupts the cascade and protects the host cells from damage. Antigens present on the CD55/DAF constitute determinant for the Cromer blood group system. CD55/DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that CD55/DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology. There are two variants of CD55 encoded by alternatively spliced transcripts, the predominant variant is a GPI-anchored membrane form ubiquitously expressed on cells exposed to plasma complement proteins, whereas a soluble form present at much lower level.

References

1. Bergelson, JM. et al., 1994, Proc. Natl. Acad. Sci. USA. 91: 6245-8.
2. Terstappen, LW. et al., 1992, J. Leuro. Biol. 52: 652-60.
3. Liu, J. et al., 2005, J. Exp. Med. 201: 567-77.
4. Madjd, Z. et al., 2004, Clin. Cancer. Res. 10: 2797-803.
5. Mikesch, JH. et al., 2007, Cell. Oncol. 28: 223-32.